Welcome to our dedicated page for Nuvectis Pharma news (Ticker: NVCT), a resource for investors and traders seeking the latest updates and insights on Nuvectis Pharma stock.
Nuvectis Pharma, Inc. reports developments as a clinical-stage biopharmaceutical company focused on precision medicines for serious oncology indications. Company news centers on NXP900, an oral small-molecule inhibitor of the SRC Family of Kinases, including SRC and YES1, and on clinical and preclinical work in genetically or molecularly defined cancer settings.
Recurring updates include financial results, business highlights, clinical program progress, AACR and other oncology conference presentations, pharmacokinetic and pharmacodynamic findings, drug-drug interaction data, and combination-therapy research in non-small cell lung cancer and other advanced solid tumors. News also covers capital resources and financing activity tied to development operations.
Nuvectis Pharma (NVCT) will participate in two upcoming investor conferences in September 2026 to discuss its clinical-stage pipeline in complement-related diseases and oncology.
The company joins the 2026 Cantor Global Healthcare Conference for a fireside chat on Friday, September 11, 2026 at 9:10 AM ET, and the H.C. Wainwright 28th Annual Global Investment Conference for a company presentation on Monday, September 14, 2026 at 12:00 PM ET. Webcasts for both events will be accessible through links provided by the organizers and via the Investors section of Nuvectis’ website.
Nuvectis is developing ciprocopan (NXP100), a complement Factor B inhibitor and its lead candidate, recently approved in China for treating PNH patients previously untreated with complement inhibitors, as a once-daily oral option for complement-mediated diseases. Its oncology pipeline also includes NXP200, an oral brain-penetrant BRAF inhibitor targeting BRAF V600X and non-V600 mutations, and NXP900, an oral inhibitor of SRC family kinases SRC and YES1 intended to comprehensively block SRC signaling.
Nuvectis Pharma (NASDAQ: NVCT) reported second quarter 2026 results and major pipeline and financing updates. The company completed in-licensing of ex-China rights to two Haisco compounds, ciprocopan (NXP100), a once-daily oral Complement Factor B inhibitor, and NXP200, a brain-penetrant paradox-breaker BRAF inhibitor, positioning Nuvectis as a late-stage clinical development organization.
Haisco obtained July 2026 marketing approval in China for ciprocopan in PNH patients not previously treated with complement inhibitors, with a second PNH indication under review. Nuvectis plans a pre-IND FDA meeting and IND submission for ciprocopan and an IND for NXP200 in 4Q 2026. A $115 million follow-on offering in July 2026, anchored by healthcare investors, is expected to extend the cash runway into 1H 2029. Q2 2026 net loss was $7.0 million on R&D expenses of $4.7 million and G&A of $2.5 million, with June 30, 2026 cash of $22.2 million before the offering.
Nuvectis (NASDAQ: NVCT) announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from China’s NMPA for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) patients previously untreated with complement inhibitors.
The approval is based on a head-to-head Phase 3 trial versus Soliris (eculizumab) in treatment-naive PNH patients, in which ciprocopan met all primary and secondary endpoints and showed superior efficacy and favorable safety. Haisco developed and will commercialize ciprocopan in China, while Nuvectis holds exclusive rights outside Greater China, India and certain Southeast Asian countries.
Nuvectis Pharma (NASDAQ: NVCT)/b) reported that ciprocopan (NXP100), a once-daily oral Complement Factor B inhibitor, received marketing approval from China’s NMPA for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) patients previously untreated with complement inhibitors.This is the first global approval of a once-daily oral Factor B inhibitor and is based on a head-to-head Phase 3 trial versus Soliris in treatment‑naive PNH patients, where ciprocopan met all primary and secondary endpoints, showed superior hemoglobin responses and transfusion avoidance, and had no discontinuations due to adverse events. Haisco developed and controls ciprocopan in China, while Nuvectis holds exclusive rights outside Greater China, India and parts of Southeast Asia.
Nuvectis Pharma (Nasdaq: NVCT) priced an underwritten public offering of 5,000,000 common shares at $20.00 per share, targeting $100 million in gross proceeds, plus a 30-day option for 750,000 additional shares.
Proceeds will fund NXP100, NXP200, NXP900, hiring, capital spending and general corporate purposes.
Nuvectis Pharma (Nasdaq: NVCT) announced it has commenced an underwritten public offering of common stock, with all shares offered by the company and a 30-day option for underwriters to purchase up to an additional 15% of shares.
Proceeds are planned to fund NXP100, NXP200, NXP900 development, hiring, capital expenditures, public-company costs, and general corporate purposes.
Nuvectis (NASDAQ: NVCT) signed a license agreement with Haisco for exclusive ex-China rights to two clinical-stage assets: Complement Factor B inhibitor NXP100 and paradox-breaker BRAF inhibitor NXP200.
The deal adds late-stage programs in complement-mediated diseases and oncology, with patents to 2042–2043 and up to $1.461B in potential payments plus tiered royalties, subject to financing conditions.
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company developing precision oncology medicines for serious unmet medical needs, announced management participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026.
The company’s presentation, led by Chairman and CEO Ron Bentsur, is scheduled from 9:00–9:30 AM EDT in New York, NY. A live webcast will be accessible in the Investors section of the Nuvectis website.
Nuvectis Pharma (NASDAQ: NVCT) reported Q1 2026 results and clinical updates on May 5, 2026. Cash and cash equivalents were $25.1 million as of March 31, 2026, down from $31.6 million at year-end. Net loss was $6.1 million for Q1 2026. The NXP900 Phase 1b program continues to enroll in the US, with preclinical data presented at AACR showing synergy with sotorasib in NSCLC models. Management expects a preliminary Phase 1b data readout in summer 2026 and cited continued financial discipline while advancing clinical milestones.
Nuvectis Pharma (NASDAQ: NVCT) announced poster presentations for its clinical candidate NXP900 at the 2026 American Association for Cancer Research Meeting (AACR), April 17–22, 2026 in San Diego, CA.
Three abstracts will be presented April 21–22 covering synergy with KRAS inhibitors in NSCLC, resistance mechanisms in cholangiocarcinoma, and targeting MDSCs via SRC family kinase inhibition. Specific session times and titles are listed for each poster.